Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UT Southwestern researchers find clues to TB drug resistance

30.03.2010
Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

The good news: A type of blood pressure medication shows promise at overcoming some drug-resistant tuberculosis, at least in the laboratory. The bad news: The Mycobacterium tuberculosis bacterium, which causes the disease, might be resistant to treatment in more people than previously thought.

Dr. Tawanda Gumbo, associate professor of internal medicine at UT Southwestern and senior author of the studies, said the research challenges current thinking about how the TB bacterium works in the body as well as how best to kill it.

His published findings come after the Dallas County Department of Health and Human Services announced this month that while the number of TB cases diagnosed in Dallas County dropped to 195 in 2009 from 219 a year earlier, the county's rate of infection is still 1.5 times higher than the national rate.

In the first study, available online and in the April 15 edition of The Journal of Infectious Diseases, Dr. Gumbo and his colleagues used an experimental apparatus to simulate the way TB bacteria grow in the human lung. When they exposed the bacteria to drugs commonly used to treat the disease – ethambutol and isoniazid – the bacterial cells activated a cellular mechanism that pumps each drug out of the cells. The pumping action enables the rapid emergence of high-level resistance to the drugs whether administered together as well as individually, Dr. Gumbo said.

"We treat TB with multiple drugs essentially to protect each other from resistance, but yet we've been puzzled with why you find resistance to both drugs together," Dr. Gumbo said. "Our findings make sense – it is more efficient from the bacteria's viewpoint to employ the same mechanism get rid of multiple attackers, whether they strike alone or at the same time."

Resistance was drastically reduced, however, when the researchers gave the blood-pressure drug reserpine – which is known to block this pumping action – to the TB cells before administering ethambutol and isoniazid.

"There is already a known solution to this problem," Dr. Gumbo said. "Hopefully now we can reduce resistance to TB treatment drugs."

Current TB treatment uses multiple drugs simultaneously, in hopes of preventing drug resistance. The next step in his research, Dr. Gumbo said, is to test all the first-line drug treatments together with the pump blocker in humans.

If first-line drugs won't work to kill TB, the person is said to have multidrug-resistant TB and doctors proceed to second-line treatments, which are usually more expensive and more toxic and take longer to work, Dr. Gumbo said.

In Dr. Gumbo's second study, available online and in the April edition of Antimicrobial Agents and Chemotherapy, the researchers found that more people might harbor drug-resistant TB than currently believed because tests that detect the TB bacteria's resistance don't account for variations in height, weight and other factors among TB patients.

Guidelines for testing whether a person is infected with a drug-resistant TB strain were developed more than 40 years ago. They involve determining the lowest concentration of a drug that will kill at least 95 percent of the TB bacteria in a patient. The TB is said to be resistant to the drug if more than 1 percent of TB still grows at that concentration.

Dr. Gumbo said those guidelines are useful for showing trends, but are not effective for predicting how an individual will respond to therapy. Recommended drug concentrations and dosages, for example, don't account for factors such as body weight, height, race and how much food a person ate before being tested.

"Science has evolved," Dr. Gumbo said. "We have better tools now so we can do more and predict better treatment."

In the second study, he again simulated TB in the human lung and virtually simulated eight clinical trials involving 10,000 patients. The computer simulation factored in pharmacokinetics (how a body handles a drug based on heterogeneous factors) to determine how likely a dose of a given drug is to kill TB.

Dr. Gumbo's research team found that the concentrations typically used in practice are too low, leading people to think they have treatable TB, when in fact their disease might be resistant to common drugs.

"There is likely more multidrug-resistant TB than previously thought – possibly up to four times as much," Dr. Gumbo said. "That means some people may be getting underdosed with medicine weaker than the disease, and they die."

The next step, Dr. Gumbo said, is to confirm these computer-driven results in patients.

Dr. Gumbo's research is funded by a 2007 National Institutes of Health Director's New Innovator Award, which supports bold ideas from some of the nation's most innovative early-career scientists.

Other UT Southwestern researchers participating in the research were Sandirai Musuka, research associate in internal medicine, and Dr. Shashikant Srivastava, postdoctoral researcher in internal medicine. Researchers from Texas Tech University Health Sciences Center's School of Pharmacy also were involved in the study published in The Journal of Infectious Diseases.

Visit http://www.utsouthwestern.org/infectiousdiseases to learn more about UT Southwestern's clinical services for infectious diseases, including tuberculosis.

This news release is available on our World Wide Web home page at http://www.utsouthwestern.edu/home/news/index.html

To automatically receive news releases from UT Southwestern via e-mail, subscribe at www.utsouthwestern.edu/receivenews

Kristen Holland Shear | EurekAlert!
Further information:
http://www.utsouthwestern.edu

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>